KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Depreciation and Depletion (2023 - 2025)

Historic Depreciation and Depletion for Vir Biotechnology (VIR) over the last 3 years, with Q3 2025 value amounting to $2.9 million.

  • Vir Biotechnology's Depreciation and Depletion changed 0.0% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.3 million, marking a year-over-year decrease of 2848.1%. This contributed to the annual value of $14.2 million for FY2024, which is 2486.77% down from last year.
  • According to the latest figures from Q3 2025, Vir Biotechnology's Depreciation and Depletion is $2.9 million, which was down 0.0% from $2.9 million recorded in Q2 2025.
  • Vir Biotechnology's 5-year Depreciation and Depletion high stood at $5.5 million for Q1 2023, and its period low was $2.7 million during Q4 2024.
  • For the 3-year period, Vir Biotechnology's Depreciation and Depletion averaged around $3.8 million, with its median value being $4.2 million (2024).
  • Per our database at Business Quant, Vir Biotechnology's Depreciation and Depletion plummeted by 3720.93% in 2024 and then changed by 0.0% in 2025.
  • Over the past 3 years, Vir Biotechnology's Depreciation and Depletion (Quarter) stood at $4.3 million in 2023, then tumbled by 37.21% to $2.7 million in 2024, then rose by 7.41% to $2.9 million in 2025.
  • Its Depreciation and Depletion was $2.9 million in Q3 2025, compared to $2.9 million in Q2 2025 and $2.8 million in Q1 2025.